Genomic Vision (GV.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:GV - FR0011799907 - Common Stock
0.0018 EUR
+0 (+5.88%)
We assign a fundamental rating of 0 out of 10 to GV. GV was compared to 86 industry peers in the Biotechnology industry. GV has a bad profitability rating. Also its financial health evaluation is rather negative. GV is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year GV has reported negative net income.
- In the past year GV has reported a negative cash flow from operations.
1.2 Ratios
- With a Return On Assets value of -268.44%, GV is not doing good in the industry: 89.74% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -268.44% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-93.6%
ROA(5y)-88.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for GV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- GV does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, GV has more shares outstanding
- Compared to 1 year ago, GV has a worse debt to assets ratio.
2.2 Solvency
- GV has an Altman-Z score of -20.15. This is a bad value and indicates that GV is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -20.15, GV is doing worse than 91.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.15 |
ROIC/WACCN/A
WACC5.63%
2.3 Liquidity
- GV has a Current Ratio of 0.41. This is a bad value and indicates that GV is not financially healthy enough and could expect problems in meeting its short term obligations.
- GV has a worse Current ratio (0.41) than 94.87% of its industry peers.
- GV has a Quick Ratio of 0.41. This is a bad value and indicates that GV is not financially healthy enough and could expect problems in meeting its short term obligations.
- GV has a Quick ratio of 0.36. This is amonst the worse of the industry: GV underperforms 94.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.41 | ||
| Quick Ratio | 0.36 |
3. Growth
3.1 Past
- GV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.12%.
- The Revenue has been growing slightly by 6.74% in the past year.
- GV shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -13.68% yearly.
EPS 1Y (TTM)-14.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.36%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-16.62%
Revenue growth 5Y-13.68%
Sales Q2Q%16.05%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- GV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for GV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:GV (11/3/2023, 7:00:00 PM)
0.0018
+0 (+5.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap693.19K
Revenue(TTM)1.11M
Net Income(TTM)-10.62M
Analysts35
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.11
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -268.44% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-93.6%
ROA(5y)-88.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 29.31% | ||
| Cap/Sales | 32.67% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.41 | ||
| Quick Ratio | 0.36 | ||
| Altman-Z | -20.15 |
F-Score3
WACC5.63%
ROIC/WACCN/A
Cap/Depr(3y)27.39%
Cap/Depr(5y)20.59%
Cap/Sales(3y)11.06%
Cap/Sales(5y)7.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.36%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-16.62%
Revenue growth 5Y-13.68%
Sales Q2Q%16.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-71.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.92%
OCF growth 3YN/A
OCF growth 5YN/A
Genomic Vision / GV.PA FAQ
What is the ChartMill fundamental rating of Genomic Vision (GV.PA) stock?
ChartMill assigns a fundamental rating of 0 / 10 to GV.PA.
Can you provide the valuation status for Genomic Vision?
ChartMill assigns a valuation rating of 0 / 10 to Genomic Vision (GV.PA). This can be considered as Overvalued.
How profitable is Genomic Vision (GV.PA) stock?
Genomic Vision (GV.PA) has a profitability rating of 0 / 10.